Novo Holdings is a Danish holding and investment firm based in Copenhagen, wholly owned by the Novo Nordisk Foundation. Established in 1999, it manages the Foundation's financial assets and aims to ensure sufficient dividends to support its grant obligations for medical and scientific research. Novo Holdings primarily invests in the life science sector, maintaining a diverse portfolio that includes equities, bonds, real estate, infrastructure, and private investments. It holds a significant ownership stake in Novo Nordisk A/S and Novozymes A/S, ensuring a material influence over these companies. The firm actively participates in their governance and is committed to supporting early-stage applied research in life sciences through initiatives like Novo Seeds. By investing in both early and later-stage life science companies, Novo Holdings seeks to balance financial risk while aiming for high returns, all within a framework of shared values and management principles across the Novo Group.
Senior Partner and Head of US Principal Investments
Jon Levy
Senior Partner
Jeffrey Low, MD
Principal
Heather Ludvigsen
Senior Manager, Venture Investments
Nanna Lüneborg
Principal
Joseph Markson Ph.D
Principal, Venture Investments
Peter Moldt
Partner
Naveed Siddiqi
Senior Partner, Venture Investments
Jim Trenkle
Partner, Venture Investments
Kenneth Harrison Ph.D
Senior Partner
Past deals in Pennsylvania
Verve Therapeutics
Series B in 2021
Verve Therapeutics, Inc. is a genetic medicines company focused on innovative treatments for cardiovascular disease through gene editing. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company aims to shift the management of cardiovascular conditions from chronic treatments to single-course gene editing therapies. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are known to significantly impact blood lipid levels, a major factor in cardiovascular disease. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance its gene editing delivery technologies. The company is staffed by a team of experts in cardiovascular medicine, human genetics, and drug development, positioning itself to address the challenges of cardiovascular health effectively.
Harmony Biosciences
Venture Round in 2017
Harmony Biosciences is a commercial-stage pharmaceutical company based in Plymouth Meeting, Pennsylvania, founded in 2017. The company is dedicated to developing and commercializing innovative therapies for patients with rare neurological disorders who have unmet medical needs. Its primary product, WAKIX (pitolisant), is designed to treat narcolepsy in pediatric patients and has a unique mechanism of action that enhances histamine signaling in the brain by binding to H3 receptors. Harmony Biosciences aims to address critical therapeutic gaps in the treatment of neurological conditions, focusing on improving the quality of life for affected individuals.
Galera Therapeutics
Series B in 2016
Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Malvern, Pennsylvania, dedicated to developing innovative therapies that aim to enhance the effectiveness of radiotherapy in cancer treatment. The company’s lead product candidate, avasopasem manganese (GC4419), is a small molecule dismutase mimetic currently undergoing Phase III clinical trials for the treatment of severe oral mucositis induced by radiation in patients with head and neck cancer. Additionally, it is being tested in Phase IIa trials for radiotherapy-induced esophagitis in lung cancer patients. Galera is also advancing a second candidate, GC4711, which is in Phase I/II trials targeting pancreatic and lung cancers. The company was founded in 2012 and is committed to addressing severe side effects associated with cancer treatments to improve patient outcomes.
Galera Therapeutics
Series B in 2015
Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Malvern, Pennsylvania, dedicated to developing innovative therapies that aim to enhance the effectiveness of radiotherapy in cancer treatment. The company’s lead product candidate, avasopasem manganese (GC4419), is a small molecule dismutase mimetic currently undergoing Phase III clinical trials for the treatment of severe oral mucositis induced by radiation in patients with head and neck cancer. Additionally, it is being tested in Phase IIa trials for radiotherapy-induced esophagitis in lung cancer patients. Galera is also advancing a second candidate, GC4711, which is in Phase I/II trials targeting pancreatic and lung cancers. The company was founded in 2012 and is committed to addressing severe side effects associated with cancer treatments to improve patient outcomes.
Tarsa Therapeutics
Series B in 2014
Tarsa Therapeutics, Inc. is focused on developing therapies for the treatment and prevention of osteoporosis and related bone diseases, particularly in postmenopausal women. The company is advancing TBRIA, an oral formulation of salmon calcitonin, which aims to slow the rate of bone destruction associated with osteoporosis. Tarsa Therapeutics provides clinical programs that address both the treatment and prevention of osteoporosis, specifically targeting women who are more than five years post-menopause and may not be suitable for alternative therapies. Founded in 2009 and based in Philadelphia, Pennsylvania, Tarsa Therapeutics was previously known as Boneco, Inc.
Tarsa Therapeutics
Series A in 2010
Tarsa Therapeutics, Inc. is focused on developing therapies for the treatment and prevention of osteoporosis and related bone diseases, particularly in postmenopausal women. The company is advancing TBRIA, an oral formulation of salmon calcitonin, which aims to slow the rate of bone destruction associated with osteoporosis. Tarsa Therapeutics provides clinical programs that address both the treatment and prevention of osteoporosis, specifically targeting women who are more than five years post-menopause and may not be suitable for alternative therapies. Founded in 2009 and based in Philadelphia, Pennsylvania, Tarsa Therapeutics was previously known as Boneco, Inc.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.